Regeneron's gene therapy DB-OTO improved hearing to normal levels in a child with genetic deafness within 24 weeks in a Phase 1/2 trial.
Regeneron Pharmaceuticals reports that its investigational gene therapy DB-OTO improved hearing to normal levels in a child with profound genetic deafness within 24 weeks, and showed initial improvements in a second child at 6 weeks. Both children had otoferlin gene variants. The results come from the ongoing Phase 1/2 CHORD trial, involving infants and children affected by genetic deafness.
May 08, 2024
3 Articles